AAI 101

Drug Profile

AAI 101

Alternative Names: AAI101; OCID‐5090

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orchid Chemicals & Pharmaceuticals
  • Developer Allecra Therapeutics
  • Class Antibacterials; Penicillins; Sulfones
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gram-negative infections

Most Recent Events

  • 12 Sep 2017 No development reported - Phase-I for Gram-negative infections (In volunteers) in France (IV)
  • 08 Sep 2014 Pharmacokinetics and adverse events data from a phase I trial in healthy volunteers released by Allecra Therapeutics
  • 08 Sep 2014 Allecra Therapeutics completes a phase I trial in Healthy volunteers in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top